Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2014

View Archived Issues

UCP2 -866G/A polymorphism and genotypes as prognostic markers for ischemic stroke

Novel dual histamine H1/H4 antagonists presented for allergic conjunctivitis

New company Nurix launched with focus on the ubiquitin proteasome system

BioRestorative Therapies signs research agreement with Pfizer

IXICO gains additional Huntington's disease trial contracts

Novel TNF-alpha-expressing oncolytic adenovirus demonstrates antitumor activity

Pharmaxis' LOXL2 inhibitors show promise for fibrosis

U.S. researchers prepare novel nucleosides and prodrugs

CHMP adopts positive opinion for Plegridy as a treatment for multiple sclerosis

Retriacyl obtains FDA orphan drug status for RP

Salk's Glenn Center for Aging Research receives USD 3 million gift

Viking Therapeutics licenses five programs from Ligand Pharmaceuticals

Daiichi Sankyo receives additional indication approval in Japan for Ranmark

European researchers disclose new anti-S100-A4 MAbs

Shionogi patents novel AMPK activators for diabetes

Boehringer Ingelheim patent reports new CMV inhibitors

New E-selectin inhibitors designed by GlycoMimetics

FDA approves EkoSonic endovascular system

EMA committee makes Halaven recommendation

EMA's CHMP recommends approval of Simbrinza to reduce IOP

EMA committee hands down positive opinion on Arzerra for CLL

EMA recommends approval of Nuwiq for children and adults with hemophilia A

Elixir Medical presents results on CE Mark-approved novolimus-eluting coronary intervention systems

Pfizer rules out new offer for AstraZeneca

Taliglucerase alfa approved in Australia for Gaucher's disease

EMA's CHMP confirms negative opinion for RLX-030

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....